CD8A and leukemia: Based on the initial demonstration that polyclonal memory CD8+ T-cell responses to PRAME-specific peptides can be detectable in patients with different hematological malignancies, including AML (171), some other studies have addressed the capacity to elicit anti-leukemia response.